会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Plasma processing apparatus and plasma processing method
    • 等离子体处理装置和等离子体处理方法
    • US6092486A
    • 2000-07-25
    • US13258
    • 1998-01-26
    • Hiroshi MabuchiToshihiro HayamiShigeki Honda
    • Hiroshi MabuchiToshihiro HayamiShigeki Honda
    • C23C16/511C23C16/00C23C14/00C23F1/02
    • H01J37/32467C23C16/511H01J37/32192H01J37/32477H01J37/32522
    • The plasma processing apparatus and plasma processing method of the present invention are suitable for the application of plasma processing to etching, ashing, CVD, etc. in the manufacturing of large scale integrated circuits (LSIs) and liquid crystal display panels (LCDs), and useful for the manufacturing of LSIs and LCDs. The apparatus is characterized in that the reaction chamber has its side wall separated into an inner side wall which faces to the interior of the reaction chamber and an outer side wall which faces to the exterior of the reaction chamber, with the inner side wall being isolated electrically from other portions of the reaction chamber and not grounded electrically. This structure improves the repeatability of plasma processing. The apparatus is also characterized in that the inner side wall of reaction chamber is isolated thermally from other portions of the reaction chamber and equipped with temperature control means. This structure improves the temperature control performance for the inner side wall and also improves the maintainability of the apparatus.
    • 本发明的等离子体处理装置和等离子体处理方法适用于制造大规模集成电路(LSI)和液晶显示面板(LCD)时的等离子体处理对蚀刻,灰化,CVD等的应用, 对LSI和LCD的制造有用。 该装置的特征在于,反应室的侧壁分成面向反应室内部的内侧壁和面向反应室外部的外侧壁,内侧壁被隔离 与反应室的其它部分电连接,而不是电接地。 这种结构提高了等离子体处理的重复性。 该装置的特征还在于,反应室的内侧壁与反应室的其它部分热隔离并配备有温度控制装置。 该结构提高了内侧壁的温度控制性能,并且还提高了装置的可维护性。
    • 6. 发明授权
    • Tyrosine phosphatase inhibitors
    • 酪氨酸磷酸酶抑制剂
    • US06911468B2
    • 2005-06-28
    • US10276674
    • 2001-05-21
    • Takahiro MatsumotoNozomi KatayamaHiroshi Mabuchi
    • Takahiro MatsumotoNozomi KatayamaHiroshi Mabuchi
    • A61K31/402A61P3/10A61P43/00C07D207/32C07D207/333C07D209/12A61K31/40C07D207/30
    • C07D207/333A61K31/402C07D209/12
    • A compound of the formula (I): wherein X1 and X2 are the same or different and each is a bond or a spacer having 1 to 20 atom(s) in the main chain; one of R1 and R2 is a cycle group having substituent(s) selected from 1) an optionally substituted carboxy-C1-6 alkoxy group and 2) an optionally substituted carboxy-C1-6 aliphatic hydrocarbon group, wherein the cycle group optionally has additional substituent(s), and the other is an optionally substituted cycle group or a hydrogen atom; and R3, R4 and R5 are the same or different and each is a hydrogen atom or a substituent, or R4 may link together with R3 or R5 to form an optionally substituted ring; provided that when R3 is a hydrogen atom, R4 is a hydrogen atom and R5 is methyl, X2—R2 is not 4-cyclohexylphenyl; when R3 is 4-methoxyphenyl, R4 is a hydrogen atom and R5 is methyl, X2—R2 is not 4-methoxyphenyl; and when R1 or R2 is a hydrogen atom, the adjacent X1 or X2 is not a C1-7 alkylene; or a salt thereof exhibits a protein tyrosine phosphatase inhibitory action and is useful as a prophylactic or therapeutic agent for diabetes or the like.
    • 式(I)的化合物:其中X 1和X 2 2相同或不同,并且各自为键或具有1至20个原子的间隔基, 在主链上 R 1和R 2之一是具有选自以下的取代基的循环基团:1)任选取代的羧基-C 1-6亚烷基, 烷氧基和2)任选取代的羧基-C 1-6脂肪族烃基,其中所述环状基团任选具有另外的取代基,另一个是任选取代的环状基团或氢原子 ; 和R 3,R 4和R 5相同或不同,各自为氢原子或取代基,或R 1,R 2, 4可以与R 3或R 5连接以形成任选取代的环; 条件是当R 3为氢原子时,R 4为氢原子,R 5为甲基,X 2为氢原子, N 2 -R 2不是4-环己基苯基; 当R 3是4-甲氧基苯基时,R 4是氢原子,R 5是甲基,X 2是 -R 2不是4-甲氧基苯基; 并且当R 1或R 2 2是氢原子时,相邻的X 1或X 2不是 C 1-7亚烷基; 或其盐表现出蛋白酪氨酸磷酸酶抑制作用,可用作糖尿病等的预防或治疗剂。
    • 7. 发明授权
    • 4,1-benzoxazepines, their analogues, and their use as somatostatin agonists
    • 4,1-苯并氧氮杂,它们的类似物,以及它们作为生长抑素激动剂的用途
    • US06352982B1
    • 2002-03-05
    • US09403066
    • 1999-10-14
    • Hiroshi MabuchiNobuhiro SuzukiTakashi Miki
    • Hiroshi MabuchiNobuhiro SuzukiTakashi Miki
    • C07D26714
    • C07D231/12C07D233/56C07D243/24C07D249/08C07D267/14C07D281/10C07D413/04C07D413/06C07D413/12C07D417/06C07D417/12
    • The present invention provides a compound of the formula: wherein ring A is an optionally substituted aromatic hydrocarbon ring or aromatic heterocyclic ring; ring B is an optionally substituted aromatic hydrocarbon ring or aromatic heterocyclic ring; Z is an optionally substituted cyclic group or linear hydrocarbon group; R1 is a hydrogen atom, an optionally substituted hydrocarbon group or heterocyclic ring; R2 is an optionally substituted amino group; D is a bond or an optionally substituted divalent hydrocarbon group; E is a bond, —CON(Ra)—, —N(Ra)CO—, —N(Rb)CON(Rc)—, —N(Rd)COO—, —N(Re)SO2—, —COO—, —N(Rf)—, —O—, —S— —SO—, —SO2—, (in which Ra, Rb, Rc, Rd, Re and Rf are respectively a hydrogen atom or an optionally substituted hydrocarbon group); G is a bond or an optionally divalent substituted hydrocarbon group; L is a divalent group; ring B may form an optionally substituted non-aromatic condensed nitrogen-containing heterocyclic ring by combining with R2; X is two hydrogen atoms, an oxygen atom or a sulfur atom; is a single bond or a double bond, and Y is a nitrogen atom when is a double bond, or an oxygen atom, —N(R4)— (in which R4 is a hydrogen atom, an optionally substituted hydrocarbon group or an acyl group) or S(O)n (in which n is 0, 1 or 2) when is a single bond, or a salt thereof, which have somatostatin receptor agonistic action.
    • 本发明提供下式的化合物:其中环A是任选取代的芳族烃环或芳族杂环; 环B是任选取代的芳族烃环或芳族杂环; Z是任选取代的环状基团或直链烃基; R1是氢原子,任选取代的烃基或杂环; R2是任选取代的氨基; D是键或任选取代的二价烃基; E是键,-CON(Ra) - , - N(Ra)CO-,-N(Rb)CON(Rc) - , - N(Rd)COO-,-N(Re)SO2-,-COO- ,-N(R f) - , - O - , - S - -SO - , - SO 2 - (其中Ra,Rb,Rc,Rd,Re和Rf分别为氢原子或任选取代的烃基)。 G是键或任选的二价取代的烃基; L是二价基团;环B可以与R2结合形成任选取代的非芳族稠合含氮杂环; X是两个氢原子,一个氧原子或一个硫原子; 是单键或双键,当是双键或氧原子-N(R4) - (其中R4是氢原子,任选取代的烃基或酰基) )或S(O)n(其中n为0,1或2),当是单键时,或 其盐,其具有生长抑素受体激动作用。